Tim Heise
Tim Heise, MD is an expert in Endocrinology at Profil Institute for Metabolic Research (Germany). As of October 2026, ScienceLeadR ranks Tim Heise in the top 1% of experts worldwide for Diabetes Mellitus and Glucose Metabolism Disorders. Tim Heise has authored 321 publications, the most recent in 2026, and is an investigator in 32 clinical trials. SLR score: 1,215 (community average: 125). How the SLR is computed.
LeadR Profile
Endocrinology
Subspecialties: Pharmacy - Cardiology - Gastroenterology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Dr Heise is Chief Scientific Officer and Chairman of the Board of Directors of the private research institute Profil in Neuss, Germany. Founded in 1999 by Dr Heise and Dr Lutz Heinemann, Profil became known as the premier source of solutions to the challenging early phase studies of experimental diabetes and obesity treatments often using sophisticated methodology like the glucose clamp technique in combination with isotope dilution, biopsies and/or indirect calorimetry.
Dr Heise has led numerous studies in people with type 1 or type 2 diabetes, obesity, pre-diabetes and insulin resistance. His research focus is the pharmacological properties of antidiabetic and weight-loss drugs, in particular novel insulin preparations and incretin-based therapies. In addition, his study team at Profil has gained outstanding reputation for the evaluation of medical devices.
Before establishing Profil, Dr Heise worked for more than 7 years at the Clinic for Nutrition and Metabolic Diseases at the Heinrich-Heine-University Düsseldorf (Head Prof Michael Berger). During this time, he was responsible for the diabetes and obesity outpatient clinics and took care of patients in structured teaching and treatment programs for type 1 and type 2 diabetes.
Dr Heise has published more than 250 scientific papers and reviews. He is a member of the Editorial Boards of Diabetes, Obesity and Metabolism, and Diabetes Technology & Therapeutics.
Organizations
Career arc: 1994 - 2026
Number : 321
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial. PMID 42229460 — diabetes mellitus, glucagon-like peptide 1, cells, insulin, insulin secretion, drug-related side effects and adverse reactions, therapeutics, diabetes mellitus, type 2 | Diabetes Obes Metab | 2026 | 0 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. PMID 42017294 — safety, anti-obesity agents, therapeutics, overweight, pharmacokinetics, weight control | Diabetes Obes Metab | 2026 | 0 |
| Personal Viewpoint: Risk stratification and counseling of living kidney donor candidates with prediabetes. PMID 41759934 — diabetes mellitus, hemoglobins, fasting, glucose tolerance test, homeostasis, kidney, prediabetic state, counseling, transplantation | Am J Transplant | 2026 | 0 |
| Characterisation of steady-state pharmacokinetics and glucodynamics of once-weekly insulin efsitora alfa in individuals with type 2 diabetes. PMID 41725424 — diabetes mellitus, insulin, pharmacokinetics, diabetes mellitus, type 2 | Diabetes Obes Metab | 2026 | 0 |
| Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial). PMID 40884070 — mortality, heart failure, heart, neoplasms, self care, cardiology, therapeutics, palliative care | Eur Heart J Top journal | 2025 | 10 |
Clinical Studies 32
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
LeadR Networks
Main global connection map